APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Hepatitis B Immunoglobulin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Hepatitis B Immunoglobulin Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchHuman Hepatitis B Immunoglobulin Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Hepatitis B Immunoglobulin Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Human Hepatitis B Immunoglobulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Hepatitis B Immunoglobulin Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Hepatitis B Immunoglobulin Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Human Hepatitis B Immunoglobulin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Hepatitis B Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Hepatitis B Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Hepatitis B Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Hepatitis B Immunoglobulin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Hepatitis B Immunoglobulin market include Shanghai Institute of Biological, China Biologic, Sichuan Yuanda Shuyang, Shanghai RAAS, Shuanglin Bio-pharmacy, Boya Bio-pharmaceutical, Hualan Biological, Tiantan Biologic and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Hepatitis B Immunoglobulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Hepatitis B Immunoglobulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Hepatitis B Immunoglobulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Hepatitis B Immunoglobulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Hepatitis B Immunoglobulin Segment by Company

Shanghai Institute of Biological

China Biologic

Sichuan Yuanda Shuyang

Shanghai RAAS

Shuanglin Bio-pharmacy

Boya Bio-pharmaceutical

Hualan Biological

Tiantan Biologic

Bayer

Baxter

Octapharma

Grifols

CSL

Human Hepatitis B Immunoglobulin Segment by Type

400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)

200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)

100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)

Human Hepatitis B Immunoglobulin Segment by Application

Hepatitis B Carrier

Hepatitis B Close Contacts

Human Hepatitis B Immunoglobulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Hepatitis B Immunoglobulin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Hepatitis B Immunoglobulin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Hepatitis B Immunoglobulin significant trends, drivers, influence factors in global and regions.

6. To analyze Human Hepatitis B Immunoglobulin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Hepatitis B Immunoglobulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Hepatitis B Immunoglobulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Hepatitis B Immunoglobulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Hepatitis B Immunoglobulin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Hepatitis B Immunoglobulin industry.

Chapter 3: Detailed analysis of Human Hepatitis B Immunoglobulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Hepatitis B Immunoglobulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Hepatitis B Immunoglobulin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Hepatitis B Immunoglobulin Industry Trends Table 2. Human Hepatitis B Immunoglobulin Industry Drivers Table 3. Human Hepatitis B Immunoglobulin Industry Opportunities and Challenges Table 4. Human Hepatitis B Immunoglobulin Industry Restraints Table 5. Global Human Hepatitis B Immunoglobulin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Hepatitis B Immunoglobulin Revenue Share by Company (2021-2026) Table 7. Global Human Hepatitis B Immunoglobulin Sales Volume by Company (k units) & (2021-2026) Table 8. Global Human Hepatitis B Immunoglobulin Sales Volume Share by Company (2021-2026) Table 9. Global Human Hepatitis B Immunoglobulin Average Price (US$/unit) of Company (2021-2026) Table 10. Global Human Hepatitis B Immunoglobulin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Hepatitis B Immunoglobulin Key Company Manufacturing Base & Headquarters Table 12. Global Human Hepatitis B Immunoglobulin Company, Product Type & Application Table 13. Global Human Hepatitis B Immunoglobulin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Hepatitis B Immunoglobulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Table 18. Significant Companies of 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Table 19. Significant Companies of 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Table 20. Global Human Hepatitis B Immunoglobulin Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Human Hepatitis B Immunoglobulin Sales Volume by Type (2021-2026) & (k units) Table 22. Global Human Hepatitis B Immunoglobulin Sales Volume by Type (2027-2032) & (k units) Table 23. Global Human Hepatitis B Immunoglobulin Sales Volume Share by Type (2021-2026) Table 24. Global Human Hepatitis B Immunoglobulin Sales Volume Share by Type (2027-2032) Table 25. Global Human Hepatitis B Immunoglobulin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Human Hepatitis B Immunoglobulin Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Human Hepatitis B Immunoglobulin Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Human Hepatitis B Immunoglobulin Sales Value Share by Type (2021-2026) Table 29. Global Human Hepatitis B Immunoglobulin Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hepatitis B Carrier Table 31. Significant Companies of Hepatitis B Close Contacts Table 32. Global Human Hepatitis B Immunoglobulin Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Human Hepatitis B Immunoglobulin Sales Volume by Application (2021-2026) & (k units) Table 34. Global Human Hepatitis B Immunoglobulin Sales Volume by Application (2027-2032) & (k units) Table 35. Global Human Hepatitis B Immunoglobulin Sales Volume Share by Application (2021-2026) Table 36. Global Human Hepatitis B Immunoglobulin Sales Volume Share by Application (2027-2032) Table 37. Global Human Hepatitis B Immunoglobulin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Human Hepatitis B Immunoglobulin Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Human Hepatitis B Immunoglobulin Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Human Hepatitis B Immunoglobulin Sales Value Share by Application (2021-2026) Table 41. Global Human Hepatitis B Immunoglobulin Sales Value Share by Application (2027-2032) Table 42. Global Human Hepatitis B Immunoglobulin Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Human Hepatitis B Immunoglobulin Sales by Region (2021-2026) & (k units) Table 44. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region (2021-2026) Table 45. Global Human Hepatitis B Immunoglobulin Sales by Region (2027-2032) & (k units) Table 46. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region (2027-2032) Table 47. Global Human Hepatitis B Immunoglobulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Human Hepatitis B Immunoglobulin Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Human Hepatitis B Immunoglobulin Sales Value Share by Region (2021-2026) Table 50. Global Human Hepatitis B Immunoglobulin Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Human Hepatitis B Immunoglobulin Sales Value Share by Region (2027-2032) Table 52. Global Human Hepatitis B Immunoglobulin Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Human Hepatitis B Immunoglobulin Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Human Hepatitis B Immunoglobulin Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Human Hepatitis B Immunoglobulin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Human Hepatitis B Immunoglobulin Sales by Country (2021-2026) & (k units) Table 57. Global Human Hepatitis B Immunoglobulin Sales Market Share by Country (2021-2026) Table 58. Global Human Hepatitis B Immunoglobulin Sales by Country (2027-2032) & (k units) Table 59. Global Human Hepatitis B Immunoglobulin Sales Market Share by Country (2027-2032) Table 60. Global Human Hepatitis B Immunoglobulin Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Human Hepatitis B Immunoglobulin Sales Value Market Share by Country (2021-2026) Table 62. Global Human Hepatitis B Immunoglobulin Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Human Hepatitis B Immunoglobulin Sales Value Market Share by Country (2027-2032) Table 64. Shanghai Institute of Biological Company Information Table 65. Shanghai Institute of Biological Business Overview Table 66. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Product Portfolio Table 68. Shanghai Institute of Biological Recent Development Table 69. China Biologic Company Information Table 70. China Biologic Business Overview Table 71. China Biologic Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. China Biologic Human Hepatitis B Immunoglobulin Product Portfolio Table 73. China Biologic Recent Development Table 74. Sichuan Yuanda Shuyang Company Information Table 75. Sichuan Yuanda Shuyang Business Overview Table 76. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Product Portfolio Table 78. Sichuan Yuanda Shuyang Recent Development Table 79. Shanghai RAAS Company Information Table 80. Shanghai RAAS Business Overview Table 81. Shanghai RAAS Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Shanghai RAAS Human Hepatitis B Immunoglobulin Product Portfolio Table 83. Shanghai RAAS Recent Development Table 84. Shuanglin Bio-pharmacy Company Information Table 85. Shuanglin Bio-pharmacy Business Overview Table 86. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Product Portfolio Table 88. Shuanglin Bio-pharmacy Recent Development Table 89. Boya Bio-pharmaceutical Company Information Table 90. Boya Bio-pharmaceutical Business Overview Table 91. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Product Portfolio Table 93. Boya Bio-pharmaceutical Recent Development Table 94. Hualan Biological Company Information Table 95. Hualan Biological Business Overview Table 96. Hualan Biological Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Hualan Biological Human Hepatitis B Immunoglobulin Product Portfolio Table 98. Hualan Biological Recent Development Table 99. Tiantan Biologic Company Information Table 100. Tiantan Biologic Business Overview Table 101. Tiantan Biologic Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Tiantan Biologic Human Hepatitis B Immunoglobulin Product Portfolio Table 103. Tiantan Biologic Recent Development Table 104. Bayer Company Information Table 105. Bayer Business Overview Table 106. Bayer Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Bayer Human Hepatitis B Immunoglobulin Product Portfolio Table 108. Bayer Recent Development Table 109. Baxter Company Information Table 110. Baxter Business Overview Table 111. Baxter Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Baxter Human Hepatitis B Immunoglobulin Product Portfolio Table 113. Baxter Recent Development Table 114. Octapharma Company Information Table 115. Octapharma Business Overview Table 116. Octapharma Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Octapharma Human Hepatitis B Immunoglobulin Product Portfolio Table 118. Octapharma Recent Development Table 119. Grifols Company Information Table 120. Grifols Business Overview Table 121. Grifols Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Grifols Human Hepatitis B Immunoglobulin Product Portfolio Table 123. Grifols Recent Development Table 124. CSL Company Information Table 125. CSL Business Overview Table 126. CSL Human Hepatitis B Immunoglobulin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. CSL Human Hepatitis B Immunoglobulin Product Portfolio Table 128. CSL Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Human Hepatitis B Immunoglobulin Distributors List Table 132. Human Hepatitis B Immunoglobulin Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Human Hepatitis B Immunoglobulin Product Image Figure 2. Global Human Hepatitis B Immunoglobulin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Hepatitis B Immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Hepatitis B Immunoglobulin Sales (2021-2032) & (k units) Figure 5. Global Human Hepatitis B Immunoglobulin Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Human Hepatitis B Immunoglobulin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Image Figure 10. 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Image Figure 11. 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Image Figure 12. Global Human Hepatitis B Immunoglobulin Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Human Hepatitis B Immunoglobulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Human Hepatitis B Immunoglobulin Sales Volume Share by Type (2021-2032) Figure 15. Global Human Hepatitis B Immunoglobulin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Human Hepatitis B Immunoglobulin Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Human Hepatitis B Immunoglobulin Sales Value Share by Type (2021-2032) Figure 18. Hepatitis B Carrier Image Figure 19. Hepatitis B Close Contacts Image Figure 20. Global Human Hepatitis B Immunoglobulin Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Human Hepatitis B Immunoglobulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Human Hepatitis B Immunoglobulin Sales Volume Share by Application (2021-2032) Figure 23. Global Human Hepatitis B Immunoglobulin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Human Hepatitis B Immunoglobulin Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Human Hepatitis B Immunoglobulin Sales Value Share by Application (2021-2032) Figure 26. Global Human Hepatitis B Immunoglobulin Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Human Hepatitis B Immunoglobulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Human Hepatitis B Immunoglobulin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Human Hepatitis B Immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 31. North America Human Hepatitis B Immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Human Hepatitis B Immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Human Hepatitis B Immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Human Hepatitis B Immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Human Hepatitis B Immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Human Hepatitis B Immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 37. South America Human Hepatitis B Immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Human Hepatitis B Immunoglobulin Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Human Hepatitis B Immunoglobulin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Human Hepatitis B Immunoglobulin Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Human Hepatitis B Immunoglobulin Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
  • 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
  • 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
Applications
  • Hepatitis B Carrier
  • Hepatitis B Close Contacts
Companies covered
  • Shanghai Institute of Biological
  • China Biologic
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Shuanglin Bio-pharmacy
  • Boya Bio-pharmaceutical
  • Hualan Biological
  • Tiantan Biologic
  • Bayer
  • Baxter
  • Octapharma
  • Grifols
  • CSL

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Hepatitis B Immunoglobulin Sales Value (2021-2032)
  4. 1.2.2 Global Human Hepatitis B Immunoglobulin Sales Volume (2021-2032)
  5. 1.2.3 Global Human Hepatitis B Immunoglobulin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Hepatitis B Immunoglobulin Market Dynamics
  1. 2.1 Human Hepatitis B Immunoglobulin Industry Trends
  2. 2.2 Human Hepatitis B Immunoglobulin Industry Drivers
  3. 2.3 Human Hepatitis B Immunoglobulin Industry Opportunities and Challenges
  4. 2.4 Human Hepatitis B Immunoglobulin Industry Restraints
3 Human Hepatitis B Immunoglobulin Market by Company
  1. 3.1 Global Human Hepatitis B Immunoglobulin Company Revenue Ranking in 2025
  2. 3.2 Global Human Hepatitis B Immunoglobulin Revenue by Company (2021-2026)
  3. 3.3 Global Human Hepatitis B Immunoglobulin Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Hepatitis B Immunoglobulin Average Price by Company (2021-2026)
  5. 3.5 Global Human Hepatitis B Immunoglobulin Company Ranking (2024-2026)
  6. 3.6 Global Human Hepatitis B Immunoglobulin Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Hepatitis B Immunoglobulin Company Product Type and Application
  8. 3.8 Global Human Hepatitis B Immunoglobulin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Hepatitis B Immunoglobulin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Hepatitis B Immunoglobulin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Hepatitis B Immunoglobulin Market by Type
  1. 4.1 Human Hepatitis B Immunoglobulin Type Introduction
  2. 4.1.1 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
  3. 4.1.2 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
  4. 4.1.3 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
  5. 4.2 Global Human Hepatitis B Immunoglobulin Sales Volume by Type
  6. 4.2.1 Global Human Hepatitis B Immunoglobulin Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Human Hepatitis B Immunoglobulin Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Human Hepatitis B Immunoglobulin Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Human Hepatitis B Immunoglobulin Sales Value by Type
  10. 4.3.1 Global Human Hepatitis B Immunoglobulin Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Human Hepatitis B Immunoglobulin Sales Value by Type (2021-2032)
  12. 4.3.3 Global Human Hepatitis B Immunoglobulin Sales Value Share by Type (2021-2032)
5 Human Hepatitis B Immunoglobulin Market by Application
  1. 5.1 Human Hepatitis B Immunoglobulin Application Introduction
  2. 5.1.1 Hepatitis B Carrier
  3. 5.1.2 Hepatitis B Close Contacts
  4. 5.2 Global Human Hepatitis B Immunoglobulin Sales Volume by Application
  5. 5.2.1 Global Human Hepatitis B Immunoglobulin Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Hepatitis B Immunoglobulin Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Human Hepatitis B Immunoglobulin Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Human Hepatitis B Immunoglobulin Sales Value by Application
  9. 5.3.1 Global Human Hepatitis B Immunoglobulin Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Human Hepatitis B Immunoglobulin Sales Value by Application (2021-2032)
  11. 5.3.3 Global Human Hepatitis B Immunoglobulin Sales Value Share by Application (2021-2032)
6 Human Hepatitis B Immunoglobulin Regional Sales and Value Analysis
  1. 6.1 Global Human Hepatitis B Immunoglobulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Hepatitis B Immunoglobulin Sales by Region (2021-2032)
  3. 6.2.1 Global Human Hepatitis B Immunoglobulin Sales by Region: 2021-2026
  4. 6.2.2 Global Human Hepatitis B Immunoglobulin Sales by Region (2027-2032)
  5. 6.3 Global Human Hepatitis B Immunoglobulin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Hepatitis B Immunoglobulin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Hepatitis B Immunoglobulin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Hepatitis B Immunoglobulin Sales Value by Region (2027-2032)
  9. 6.5 Global Human Hepatitis B Immunoglobulin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Hepatitis B Immunoglobulin Sales Value (2021-2032)
  12. 6.6.2 North America Human Hepatitis B Immunoglobulin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Hepatitis B Immunoglobulin Sales Value (2021-2032)
  15. 6.7.2 Europe Human Hepatitis B Immunoglobulin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Hepatitis B Immunoglobulin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Hepatitis B Immunoglobulin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Hepatitis B Immunoglobulin Sales Value (2021-2032)
  21. 6.9.2 South America Human Hepatitis B Immunoglobulin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Hepatitis B Immunoglobulin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Hepatitis B Immunoglobulin Sales Value Share by Country, 2025 VS 2032
7 Human Hepatitis B Immunoglobulin Country-level Sales and Value Analysis
  1. 7.1 Global Human Hepatitis B Immunoglobulin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Hepatitis B Immunoglobulin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Hepatitis B Immunoglobulin Sales by Country (2021-2032)
  4. 7.3.1 Global Human Hepatitis B Immunoglobulin Sales by Country (2021-2026)
  5. 7.3.2 Global Human Hepatitis B Immunoglobulin Sales by Country (2027-2032)
  6. 7.4 Global Human Hepatitis B Immunoglobulin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Hepatitis B Immunoglobulin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Hepatitis B Immunoglobulin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Hepatitis B Immunoglobulin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Hepatitis B Immunoglobulin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Hepatitis B Immunoglobulin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Institute of Biological
  2. 8.1.1 Shanghai Institute of Biological Company Information
  3. 8.1.2 Shanghai Institute of Biological Business Overview
  4. 8.1.3 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Product Portfolio
  6. 8.1.5 Shanghai Institute of Biological Recent Developments
  7. 8.2 China Biologic
  8. 8.2.1 China Biologic Company Information
  9. 8.2.2 China Biologic Business Overview
  10. 8.2.3 China Biologic Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 China Biologic Human Hepatitis B Immunoglobulin Product Portfolio
  12. 8.2.5 China Biologic Recent Developments
  13. 8.3 Sichuan Yuanda Shuyang
  14. 8.3.1 Sichuan Yuanda Shuyang Company Information
  15. 8.3.2 Sichuan Yuanda Shuyang Business Overview
  16. 8.3.3 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Product Portfolio
  18. 8.3.5 Sichuan Yuanda Shuyang Recent Developments
  19. 8.4 Shanghai RAAS
  20. 8.4.1 Shanghai RAAS Company Information
  21. 8.4.2 Shanghai RAAS Business Overview
  22. 8.4.3 Shanghai RAAS Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai RAAS Human Hepatitis B Immunoglobulin Product Portfolio
  24. 8.4.5 Shanghai RAAS Recent Developments
  25. 8.5 Shuanglin Bio-pharmacy
  26. 8.5.1 Shuanglin Bio-pharmacy Company Information
  27. 8.5.2 Shuanglin Bio-pharmacy Business Overview
  28. 8.5.3 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Product Portfolio
  30. 8.5.5 Shuanglin Bio-pharmacy Recent Developments
  31. 8.6 Boya Bio-pharmaceutical
  32. 8.6.1 Boya Bio-pharmaceutical Company Information
  33. 8.6.2 Boya Bio-pharmaceutical Business Overview
  34. 8.6.3 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Product Portfolio
  36. 8.6.5 Boya Bio-pharmaceutical Recent Developments
  37. 8.7 Hualan Biological
  38. 8.7.1 Hualan Biological Company Information
  39. 8.7.2 Hualan Biological Business Overview
  40. 8.7.3 Hualan Biological Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hualan Biological Human Hepatitis B Immunoglobulin Product Portfolio
  42. 8.7.5 Hualan Biological Recent Developments
  43. 8.8 Tiantan Biologic
  44. 8.8.1 Tiantan Biologic Company Information
  45. 8.8.2 Tiantan Biologic Business Overview
  46. 8.8.3 Tiantan Biologic Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Tiantan Biologic Human Hepatitis B Immunoglobulin Product Portfolio
  48. 8.8.5 Tiantan Biologic Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Human Hepatitis B Immunoglobulin Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Baxter
  56. 8.10.1 Baxter Company Information
  57. 8.10.2 Baxter Business Overview
  58. 8.10.3 Baxter Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Baxter Human Hepatitis B Immunoglobulin Product Portfolio
  60. 8.10.5 Baxter Recent Developments
  61. 8.11 Octapharma
  62. 8.11.1 Octapharma Company Information
  63. 8.11.2 Octapharma Business Overview
  64. 8.11.3 Octapharma Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Octapharma Human Hepatitis B Immunoglobulin Product Portfolio
  66. 8.11.5 Octapharma Recent Developments
  67. 8.12 Grifols
  68. 8.12.1 Grifols Company Information
  69. 8.12.2 Grifols Business Overview
  70. 8.12.3 Grifols Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Grifols Human Hepatitis B Immunoglobulin Product Portfolio
  72. 8.12.5 Grifols Recent Developments
  73. 8.13 CSL
  74. 8.13.1 CSL Company Information
  75. 8.13.2 CSL Business Overview
  76. 8.13.3 CSL Human Hepatitis B Immunoglobulin Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 CSL Human Hepatitis B Immunoglobulin Product Portfolio
  78. 8.13.5 CSL Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Hepatitis B Immunoglobulin Value Chain Analysis
  2. 9.1.1 Human Hepatitis B Immunoglobulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Hepatitis B Immunoglobulin Sales Mode & Process
  6. 9.2 Human Hepatitis B Immunoglobulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Hepatitis B Immunoglobulin Distributors
  9. 9.2.3 Human Hepatitis B Immunoglobulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst